Do Naranjo Criteria Still Apply to Ipilimumab-induced Uveitis?
Jules Gonin Eye Hospital, FAA, University of Lausanne, Switzerland.
Yan
Y
Guex-Crosier
D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D017408:Guidelines as Topic; D006801:Humans; D000074324:Ipilimumab; D009885:Ophthalmology / Q000592:standards*; D016896:Treatment Outcome; D014605:Uveitis / Q000139:chemically induced* / Q000175:diagnosis*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000074324:Ipilimumab